Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity
Alvotech's shares rose 13% after the FDA approved additional U.S. manufacturing capacity for its Humira biosimilar, Simlandi. The approval doubles production capacity and suggests past plant issues may be resolved. FDA decisions on other biosimilars are expected in Q4 2026. According to the CEO, the approval effectively doubles the drug substance manufacturing capacity for U.S. supply.
How this was made
The 30-second read
Why it matters
The capacity increase could accelerate commercialization of its Humira biosimilar and improve confidence in upcoming FDA decisions for other products.
Market read
Regulatory approval removes a major hurdle, likely driving short‑term share rally and longer‑term growth prospects.
What to watch
Potential supply chain constraints or pricing pressure from Teva could limit upside.
Background
Alvotech has previously faced FDA rejections due to plant deficiencies; this approval signals resolution of those issues.
Ticker impact
FDA approved a second production suite for Alvotech's Humira biosimilar, effectively doubling U.S. manufacturing capacity.
upward pressure as market prices in expanded capacity and potential sales growth.
Capacity expansion directly addresses previous FDA rejections and supports pending filings, improving outlook.
Market effects
Strengthens the biosimilars sector by showing regulatory clearance path for capacity upgrades.
May increase competition for Humira in the U.S., affecting pricing dynamics.
Highlights FDA's willingness to approve capacity expansions, relevant for other biotech firms.
Counterpoint
If pending filings face further delays, the capacity boost may not translate into near‑term revenue.
Key entities
- companyAlvotech
Biopharma developing biosimilars, listed on Nasdaq as ALVO.
- companyTeva Pharmaceutical Industries
Exclusive U.S. rights holder for Alvotech's Simlandi.
